Tag: Immuno-Oncology Therapies

Biomarker, Innovation

Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies

November 30, 2022

Via: HitConsultant

The company also announced dosing of the first patient in its Phase 1 clinical trial of NTX1088, Nectin’s first-in-class PVR blocker, in cancer patients with locally advanced and metastatic solid tumors. NTX1088 is a first-in-class high affinity monoclonal antibody directed […]